Intralesional Meglumine Antimoniate: Safe, Feasible and Effective Therapy for Cutaneous Leishmaniasis in Bolivia
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Population and Geographical Location
2.2. Public Health Strategies of Intervention
2.3. Clinical Intervention
2.4. Ethics Permission
2.5. Statistical Analysis
3. Results
3.1. Promotion for the Voluntary Involvement of Primary Health Care Centres Staff
3.2. Intralesional Antimony Treatment
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- World Health Organization. Leishmaniasis. Key Facts. 2022. Available online: https://www.who.int/news-room/fact-sheets/detail/leishmaniasis (accessed on 9 September 2022).
- Pan American Health Organization. Leishmaniasis: Epidemiological Report of the Americas [Internet]. No. 10, December 2021; PAHO: Washington, DC, USA, 2021; Available online: https://iris.paho.org/handle/10665.2/51742 (accessed on 9 September 2022).
- Berman, J.D. Human Leishmaniasis: Clinical, Diagnostic, and Chemotherapeutic Developments in the Last 10 Years. Clin. Infect. Dis. 1997, 24, 684–703. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Palumbo, E. Treatment strategies for mucocutaneous leishmaniasis. J. Glob. Infect. Dis. 2010, 2, 147–150. [Google Scholar] [CrossRef] [PubMed]
- Machado-Silva, A.; Guimarães, P.P.G.; Tavares, C.A.P.; Sinisterra, R.D. New perspectives for leishmaniasis chemotherapy over current anti-leishmanial drugs: A patent landscape. Expert Opin. Ther. Patents 2015, 25, 247–260. [Google Scholar] [CrossRef] [PubMed]
- Herwaldt, B.L.; Berman, J.D. Recommendations for Treating Leishmaniasis with Sodium Stibogluconate (Pentostam) and Review of Pertinent Clinical Studies. Am. J. Trop. Med. Hyg. 1992, 46, 296–306. [Google Scholar] [CrossRef]
- World Health Organization. Control of the Leishmaniases. World Health Organ 2010 Tech. Rep. Ser. 949: 186. Available online: https://apps.who.int/iris/handle/10665/44412 (accessed on 15 June 2022).
- Pan American Health Organization. Guideline for the Treatment of Leishmaniasis in the Americas, 2nd ed.; PAHO: Washington, DC, USA, 2022. [Google Scholar] [CrossRef]
- Lodi, G.; Sannino, M.; Caterino, P.; Cannarozzo, G.; Bennardo, L.; Nisticò, S.P. Fractional CO2 laser-assisted topical rifamycin drug delivery in the treatment of pediatric cutaneous leishmaniasis. Pediatr Dermatol. 2021, 38, 717–720. [Google Scholar] [CrossRef]
- Asilian, A.; Sadeghinia, A.; Faghihi, G.; Momeni, A. Comparative study of the efficacy of combined cryotherapy and intralesional Meglumine antimoniate (Meglumine antimoniate) vs. cryotherapy and intralesional Meglumine antimoniate (Meglumine antimoniate) alone for the treatment of cutaneous leishmaniasis. Int. J. Dermatol. 2004, 43, 281–283. [Google Scholar] [CrossRef]
- Oliveira-Neto, M.P.; Schubach, A.; Mattos, M.; Da Costa, S.C.G.; Pirmez, C. Intralesional therapy of American cutaneous leishmaniasis with pentavalent antimony in Rio de Janeiro, Brazil—An area of Leishmania (V.) braziliensis transmission. Int. J. Dermatol. 1997, 36, 463–468. [Google Scholar] [CrossRef]
- Ramalho, D.B.; Silva, R.E.D.; Senna, M.C.R.; Moreira, H.S.A.; Pedras, M.J.; Avelar, D.M.D.; Saraiva, L.; Rabello, A.; Cota, G. Meglumine antimoniateintralesional infiltration for localised cutaneous leishmaniasis: A single arm, open label, phase II clinical trial. Mem. Inst. Oswaldo Cruz. 2018, 113, e180200. [Google Scholar] [CrossRef] [Green Version]
- Layegh, P.; Naviafar, P.; Pezeshkpoor, F.; Moghiman, T.; Soruri, A.H. Efficacy of Cryotherapy versus Intralesional Meglumine Antimoniate (Glucantime) for Treatment of Cutaneous Leishmaniasis in Children. Am. J. Trop. Med. Hyg. 2009, 80, 172–175. [Google Scholar] [CrossRef]
- Duque, M.C.D.O.; Silva, J.J.Q.; Soares, P.A.O.; Magalhães, R.S.; Horta, A.P.A.; Paes, L.R.B.; Lyra, M.R.; Pimentel, M.I.F.; Antonio, L.D.F.; Vasconcellos, E.D.C.F.E.; et al. Comparison between systemic and intralesional meglumine antimoniate therapy in a primary health care unit. Acta Trop. 2019, 193, 176–182. [Google Scholar] [CrossRef]
- Duque, M.C.D.O.; Vasconcellos, E.D.C.F.E.; Pimentel, M.I.F.; Lyra, M.R.; Pacheco, S.J.B.; Marzochi, M.C.D.A.; Rosalino, C.M.V.; Schubach, A.D.O. Standardization of intralesional meglumine antimoniate treatment for cutaneous leishmaniasis. Rev. Soc. Bras. Med. Trop. 2016, 49, 774–776. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Farajzadeh, S.; Ahmadi, R.; Mohammadi, S.; Pardakhty, A.; Khalili, M.; Aflatoonian, M. Evaluation of the efficacy of intralesional Antimoniate of meglumine plus niosomal zinc sulphate in comparison with intralesional Antimoniate of meglumine plus cryotherapy in the treatment of acute cutaneous leishmaniasis, a randomized clinical trial. J. Parasit. Dis. 2018, 42, 616–620. [Google Scholar] [CrossRef] [PubMed]
- Soto, J.; Rojas, E.; Guzman, M.; Verduguez, A.; Nena, W.; Maldonado, M.; Cruz, M.; Gracia, L.; Villarroel, D.; Alavi, I.; et al. Intralesional Antimony for Single Lesions of Bolivian Cutaneous Leishmaniasis. Clin. Infect. Dis. 2013, 56, 1255–1260. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cabrera, E.R.; Verduguez-Orellana, A.; Rojas, M.C.; Guzmán-Rivero, M. Antimoniato de meglumine perilesional en leishmaniasis cutánea con falla terapéutica sistémica: Serie de casos. Gac. Medica Boliv. 2019, 42, 74–78. [Google Scholar] [CrossRef]
- Rojas Cabrera, E.; Guzman-Rivero, M.; Verduguez-Orellana, A.; Córdova Rojas, M.; Aranibar Aguilar, G.; Campos, M.A.; Campero Lino, E. Aplicación intralesional de antimoniales en el tratamiento de leishmaniasis cutánea. Gac. Med. Bol. 2022, 45, 6–11. [Google Scholar] [CrossRef]
- Ramírez, J.R.; Agudelo, S.; Muskus, C.; Alzate, J.F.; Berberich, C.; Barker, D.; Velez, I.D. Diagnosis of Cutaneous Leishmaniasis in Colombia: The Sampling Site within Lesions Influences the Sensitivity of Parasitologic Diagnosis. J. Clin. Microbiol. 2000, 38, 3768–3773. [Google Scholar] [CrossRef] [Green Version]
- Starfield, B.; Shi, L.; Macinko, J. Contribution of Primary Care to Health Systems and Health. Milbank Q. 2005, 83, 457–502. [Google Scholar] [CrossRef]
- Rao, M.; Pilot, E. The missing link—The role of primary care in global health. Glob. Health Action 2014, 7, 23693. [Google Scholar] [CrossRef] [Green Version]
- World Health Organisation. Primary Healthcare: Now More than Ever. Geneva: WHO. 2008 The World Health Report. Available online: https://apps.who.int/iris/handle/10665/43949 (accessed on 15 June 2022).
- Lehmann, U.; Dieleman, M.; Martineau, T. Staffing remote rural areas in middle- and low-income countries: A literature review of attraction and retention. BMC Health Serv. Res. 2008, 8, 19. [Google Scholar] [CrossRef]
- Perry, B.; Gesler, W. Physical access to primary health care in Andean Bolivia. Soc. Sci. Med. 2000, 50, 1177–1188. [Google Scholar] [CrossRef]
- Anderson, E.; Shepherd, M.; Salisbury, C. ‘Taking off the suit’: Engaging the community in primary health care decision-making. Health Expect. 2006, 9, 70–80. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bolivia, Health Ministry. Available online: https://estadisticas.minsalud.gob.bo/Reportes_Vigilancia/Form_Vigi_2021_302a.aspx (accessed on 29 July 2022).
- Ezzine Sebai, N.; Mrabet, N.; Khaled, A.; Zeglaoui, F.; Kharfi, M.; Fazaa, B.; Kamoun, M.R. Side effects of Meglumine antimoniate in cutaneous leishmaniasis: 15 cases. Tunis Med. 2010, 88, 9–11. [Google Scholar] [PubMed]
- Shanehsaz, S.M.; Ishkhanian, S. Therapeutic and adverse effects of standard-dose and low-dose Meglumine antimoniate during systemic treatment of Syrian cutaneous leishmaniasis patients. J. Pakistan Assoc. Dematol. 2014, 24, 115–121. [Google Scholar]
- De Oliveira, A.L.L.; Brustoloni, Y.M.; Fernandes, T.D.; Dorval, M.E.C.; Da Cunha, R.V.; Bóia, M.N. Severe adverse reactions to meglumine antimoniate in the treatment of visceral leishmaniasis: A report of 13 cases in the southwestern region of Brazil. Trop. Dr. 2009, 39, 180–182. [Google Scholar] [CrossRef]
- Manongi, R.N.; Marchant, T.C.; Bygbjerg, I.B.C. Improving motivation among primary health care workers in Tanzania: A health worker perspective. Hum. Resour. Health 2006, 4, 6. [Google Scholar] [CrossRef] [Green Version]
- Ministerio de Salud Bolivia. Unidad Nacional de Vigilancia Epidemiológica. Manual Práctico de Tratamiento de la Leishmaniosis. Ministerio de Salud Bolivia. 2002. Available online: http://www.bio-nica.info/biblioteca/Mollinedo2002.pdf (accessed on 29 July 2022).
- Rodríguez, D.E.; Sebastian, M.S.; Pulkki-Brännström, A.-M. “Cheaper and better”: Societal cost savings and budget impact of changing from systemic to intralesional pentavalent antimonials as the first-line treatment for cutaneous leishmaniasis in Bolivia. PLoS Negl. Trop. Dis. 2019, 13, e0007788. [Google Scholar] [CrossRef] [Green Version]
- Miranda Rodrigues, A.; Hueb, M.; Santos, T.A.R.R.D.; Fontes, C.J.F. Fatores associados ao insucesso do tratamento da leishmaniose cutânea com antimoniato de meglumina. Rev. Soc. Bras. Med. Trop. 2006, 39, 139–145. [Google Scholar] [CrossRef] [Green Version]
- Tuon, F.F.; Amato, V.S.; Graf, M.E.; Siqueira, A.M.; Nicodemo, A.C.; Neto, V.A. Treatment of New World cutaneous leishmaniasis—A systematic review with a meta-analysis. Int. J. Dermatol. 2008, 47, 109–124. [Google Scholar] [CrossRef]
- Desjeux, P.; Mollinedo, S.; Le Pont, F.; Paredes, A.; Ugarte, G. Cutaneous leishmaniasis in Bolivia. A study of 185 human cases from Alto Beni (La Paz Department). Isolation and isoenzyme characterization of 26 strains of Leishmania brasiliensis brasiliensis [corrected]. Trans. R. Soc. Trop. Med. Hyg. 1987, 81, 742–746. [Google Scholar] [CrossRef]
- Revollo, S.; Dimier-David, L.; David, C.; Lyevre, P.; Camacho, C.; Dedet, J. Isoenzyme characterization of Leishmania braziliensis braziliensis isolates obtained from Bolivian and Peruvian patients. Trans. R. Soc. Trop. Med. Hyg. 1992, 86, 388–391. [Google Scholar] [CrossRef]
- Rojas, E.; Parrado, R.; Delgado, R.; Reithinger, R.; Garcia, A.L. Leishmaniasis in Chaparé, Bolivia. Emerg. Infect. Dis. 2009, 15, 678–680. [Google Scholar] [CrossRef] [PubMed]
- Al-Dabbagh, S.A.; Sulaiman, H.M.; Abdulkarim, N.A. Workload assessment of medical doctors at primary health care centers in the Duhok governorate. Hum. Resour. Health 2022, 19 (Suppl. S1), 117. [Google Scholar] [CrossRef] [PubMed]
- Okoroafor, S.C.; Ahmat, A.; Osubor, M.; Nyoni, J.; Bassey, J.; Alemu, W. Assessing the staffing needs for primary health care centers in Cross River State, Nigeria: A workload indicators of staffing needs study. Hum. Resour. Health 2022, 19 (Suppl. S1), 108. [Google Scholar] [CrossRef]
- Castro, M.D.M.; Cossio, A.; Velasco, C.; Osório, L. Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study. PLoS Negl. Trop. Dis. 2017, 11, e0005515. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Palacios, R.; Grajalew, L.F.; Ochoa, M.T.; Osorio, L. Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species. Am. J. Trop. Med. Hyg. 2001, 64, 187–193. [Google Scholar] [CrossRef] [PubMed]
First Period (2019) | Second Period (2020) | Third Period (2021) | |||
---|---|---|---|---|---|
Primary Health Care Centre | Settlement Region | Primary Health Care Centre | Settlement Region | Primary Health Care Centre | Settlement Region |
Chipiriri | Villages in the Indigenous Park /Amazonian rainforest | Santísima Trinidad | Villages in the Indigenous Park /Amazonian rainforest | El Abra | Urbanized town/ inter-Andean valleys |
Ichoa | |||||
Independencia | |||||
Tacopaya | |||||
Chimoré | Urbanized town/Amazonian rainforest | Entre Ríos | Urbanized town/Amazonian rainforest | Ironcollo | |
Pilot Centre: CUMETROP (Cochabambacity; inter-Andean valleys) |
Ulcer Conditions at the End of the Intralesional Treatment | Primary Health Care Centres Settlement | ||||
---|---|---|---|---|---|
Villages in the Amazonian Rainforest/Indigenous Park | Urbanised Town in the Amazonian Rainforest | Urbanised Town in the Inter-Andean Valleys | CUMETROP (Pilot Centre), Cochabamba City | ||
Patient with single ulcer n = 117 | Healing | 2 (2) | 1 (1) | - | 1 (1) |
Ulcer area partial reduction | 83 (71) | 6 (5) | 5 (4) | 13 (11) | |
Ulcer area enlargement | 3 (3) | 1 (1) | - | 2 (1) | |
Patients with two ulcers n = 35 | Healing | 2 (6) | - | - | - |
Ulcer area partial reduction | 26 (74) | 1 (3) | - | 5 (14) | |
Ulcer area enlargement | 1 (3) | - | - | - |
Ulcer Conditions | First Month Post-Tx. | Third Month Post-Tx. | Sixth Month Post-Tx. | |
---|---|---|---|---|
Patient with a single ulcer n = 117 | Healing | 53 (45) | 70 (60) | 85 (73) |
Partial reduction | 30 (26) | 13 (11) | - | |
Without changes | 2 (2) | 5 (4) | - | |
Increasing | 3 (3) | 1 (1) | - | |
Withdrawal | 1(1) | - | - | |
Therapeutic Failure | 2 (2) | 1 (1) | 5 (4) | |
No follow up | 26 (22) | 27 (23) | 27 (23) | |
Patients with two ulcers n = 35 | Healing | 23 (66) | 29 (83) | 31 (89) |
Partial reduction | 7 (20) | 2 (6) | - | |
Without changes | 1(3) | - | - | |
Increasing | - | - | - | |
Withdrawal | - | - | - | |
Therapeutic Failure | - | - | 1 (3) | |
No follow up | 4 (11) | 4 (11) | 3 (9) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Rojas Cabrera, E.; Verduguez-Orellana, A.; Tordoya-Titichoca, I.J.; Sejas, C.; Ledezma, R.; Álvarez, I.; Limachi-Choque, J.; Ortuño-Gutiérrez, N.; Córdova Rojas, M.; Guzman-Rivero, M. Intralesional Meglumine Antimoniate: Safe, Feasible and Effective Therapy for Cutaneous Leishmaniasis in Bolivia. Trop. Med. Infect. Dis. 2022, 7, 286. https://doi.org/10.3390/tropicalmed7100286
Rojas Cabrera E, Verduguez-Orellana A, Tordoya-Titichoca IJ, Sejas C, Ledezma R, Álvarez I, Limachi-Choque J, Ortuño-Gutiérrez N, Córdova Rojas M, Guzman-Rivero M. Intralesional Meglumine Antimoniate: Safe, Feasible and Effective Therapy for Cutaneous Leishmaniasis in Bolivia. Tropical Medicine and Infectious Disease. 2022; 7(10):286. https://doi.org/10.3390/tropicalmed7100286
Chicago/Turabian StyleRojas Cabrera, Ernesto, Aleida Verduguez-Orellana, Igberto J. Tordoya-Titichoca, Ccoya Sejas, Rebeca Ledezma, Ingrid Álvarez, Jhonny Limachi-Choque, Nimer Ortuño-Gutiérrez, Marisol Córdova Rojas, and Miguel Guzman-Rivero. 2022. "Intralesional Meglumine Antimoniate: Safe, Feasible and Effective Therapy for Cutaneous Leishmaniasis in Bolivia" Tropical Medicine and Infectious Disease 7, no. 10: 286. https://doi.org/10.3390/tropicalmed7100286